Best of cannabinoid science this week...
For chronic pain & PEA, a meta-analysis including eighteen studies & ~1200 patients found that PEA reduced pain and & enhanced quality of life
Meta-Analysis of Palmitoylethanolamide in Pain Management: Addressing Literature Gaps and Enhancing Understanding
In people getting dental implant surgery, taking 1200 milligrams of ultra-micronized PEA for a month after the surgery led to significantly reduced postoperative swelling, pain & trismus (overly tightened jaw muscles)
Efficacy of Ultra-Micronized Palmitoylethanolamide 600 MG (UM-PEA) for Sub-Lingual Use on Postoperative Course after Dental Implant Surgery: Multicentric Randomized Trial
In Crohn's disease, a meta-analysis found cannabis users had higher remission rates & improved quality of life
Cannabis use in Crohn’s disease: a systematic review and meta-analysis of randomized controlled trials (RCTs)
In children with drug-resistant encephalopathies (brain swelling that causes developmental & epileptic symptoms) their CBD exposure increased when taken with food
Population pharmacokinetics of cannabidiol and the impact of food and formulation on systemic exposure in children with drug-resistant developmental and epileptic encephalopathies
For Parkinson's disease, a case report on cannabis oil restoring mobility, appetite & mood
Cannabis oil in treating Parkinson’s disease: improvement of motor and non-motor symptoms: a case report
In a person with White Sutton Syndrome (a genetic mutation of intellectual disabilities, developmental delays & epilepsy), after the failure of many conventional antiseizure medications, the off-label use of CBD caused complete remission from seizures
White Sutton Syndrome and cannabidiol: an update on a reported patient with a successful response to off-label therapy
In a case report someone with both Lennox–Gastaut Syndrome (the severe childhood epilepsy) & Alpha-1,3-Mannosyltransferase-Congenital Disorder of Glycosylation (ALG3-CDG: a rare genetic disorder of early neurological abnormalities, abnormal facial features & eye problems), CBD & changes to diet led to seizure freedoms for over 13 months, significant improvements to EEG scans and percent enhanced developmental outcomes
First case report of effective and safe application of cannabidiol to treat concurrent ALG3-CDG and Lennox–Gastaut Syndrome
In horses, there were no adverse effects from CBD or CBDA (1 mg/kg)
Chronic oral dosing of cannabidiol and cannabidiolic acid full-spectrum hemp oil extracts has no adverse effects in horses: a pharmacokinetic and safety study
For neuropsychiatric disorders, a review of how CBD's ability to bind to many receptors powers its efficacy (great chart!)
Therapeutic potential of cannabidiol polypharmacology in neuropsychiatric disorders
And for neurological disorders, a review of 47 clinical trials found the most evidence for multiple sclerosis, fibromyalgia & Parkinson's disease
Therapeutic Potential of Cannabinoids in Neurological Conditions: A systematic Review of Clinical Trials
For autism, a review of CBD-rich extracts covering 350+ people noted improvements “in behavioral symptoms, social responsiveness, and communication, but cognitive benefits were less consistent”
The Evolving Role of Cannabidiol-Rich Cannabis in People with Autism Spectrum Disorder: A Systematic Review
For pediatric health conditions, a review of 10 studies of cannabis products for autism, cancer, treatment-resistant epilepsy & Sturge-Weber syndrome
Use of Cannabis-Based Medical Products for Pediatric Health Conditions: A Systematic Review of the Recent Literature
For migraines, a review of the efficacy & mechanisms of cannabinoids
Endocannabinoids, Phytocannabinoids, and Migraine
In epilepsy, a review on the neuroprotective effects of CBD & THC
Assessing the neuroprotective benefits of Cannabis sativa in epilepsy management
For post-organ transplant care, a review of using CBD for its anti-inflammatory effects
Utilization of Cannabidiol in Post-Organ-Transplant Care
For chronic pain, a review on using the cannabinoids
Cannabis for Chronic Pain: Mechanistic Insights and Therapeutic Challenges
For CBG, a review of its molecular actions & therapeutic effects (great charts!)
Cannabigerol (CBG): A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential
For beta-caryophyllene (one of the most common terpenes in cannabis), a review of its wide-ranging effects & its ability to activate the CB2 receptor
A Systemic Review of Beta-Caryophyllene
In a mouse model of pain from colitis, CBD, CBG, CBC & CBDV all reduced visceral hypersensitive pain
Entourage effects of non-psychotropic cannabinoids (npCBs) on visceral sensitivity in experimental colitis
In a mouse model of kidney damage from chemotherapy treatment, cannabis extract improved urinary parameters, restored migratory capacity & prevented apoptosis (programmed cellular suicide)
Lebanese Cannabis sativa L. extract protects from cisplatin-induced nephrotoxicity in mice by inhibiting podocytes apoptosis
In a mouse model of muscular dystrophy, full-spectrum CBD oil decreased inflammation, reduced scarring & improved muscle parameters
Treatment With Full‐Spectrum Cannabidiol Oil Improved the Pathological Findings of Dystrophic Mutant Mice
In an elderly rat model of intestinal ischemia (loss of blood flow), CBD significantly reduced intestinal injury & increased absorptive function
Cannabidiol as prophylactic treatment for intestinal ischaemia reperfusion injury in elderly rats
In a mouse & tissue model of atopic dermatitis (eczema, dry itchy inflamed skin), CBG downregulated inflammatory markers via the JAK/STAT/NFκB
Anti-Inflammatory Effects of Cannabigerol In Vitro and In Vivo Are Mediated Through the JAK/STAT/NFκB Signaling Pathway
In a mouse model of toxicity from cadmium, CBD reversed oxidative stress markers, reduced proinflammatory cytokines & protected the liver & kidney from damage
Investigation of Cannabidiol's Protective Effects on Cadmium‐Induced Toxicity in Mice
In a neuronal model of pain, CBD, CBG & CBN inhibited the voltage-gated sodium channels for less excitability of pain signals with CBG being the strongest
Nav1.8, an analgesic target for nonpsychotomimetic phytocannabinoids
Comments